The four pillars of heart failure treatment
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Four classes of medicine, taken together, substantially reduce death and hospital admission in heart failure with reduced ejection fraction. Clinicians call them the four pillars, or guideline-directed medical therapy.
Each blocks one of the body's harmful compensations. The benefit comes from having all four, not from perfecting any one of them.
Related pages: Heart failure
The bottom line
- The four pillars are ARNI or ACE inhibitor or ARB, beta blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor.
- All four together reduce mortality substantially more than any one alone.
- They are started at low doses and increased gradually.
- Many people remain on incomplete therapy, and that gap is a major cause of avoidable harm.
- SGLT2 inhibitors also benefit heart failure with preserved ejection fraction.
- The best order and speed of starting the four.
- Which treatments beyond SGLT2 inhibitors help HFpEF.
- Whether therapy can ever safely be withdrawn after recovery.
The story, step by step
- 1. Pillar one ()
- 2. Pillar two ()
- 3. Pillar three ()
- 4. Pillar four ()
- 5. Using them together ()
- 6. HFpEF ()
What the evidence labels mean
ARNI, or ACE inhibitor, or ARB
What happens
Block angiotensin, boost natriuretic peptides.
What the research shows
- ACE inhibitors such as lisinopril and ramipril block production of angiotensin II, reducing vasoconstriction, fluid retention and fibrosis. They were the first drugs shown to prolong life in heart failure.
- ARBs such as losartan and candesartan block the same system at the receptor and are used when an ACE inhibitor causes a cough.
- An ARNI, sacubitril-valsartan, combines an ARB with a drug that prevents breakdown of the body's own natriuretic peptides, and outperformed an ACE inhibitor in a head-to-head trial.
- An ARNI is now generally preferred where it is available and affordable.
- Switching from an ACE inhibitor to an ARNI requires a 36-hour gap, because taking both together risks angioedema, a dangerous swelling of the airway.
- Side effects include low blood pressure, a rise in potassium and reduced kidney function. A modest, stable rise in creatinine is expected and is not a reason to stop.
Why it matters
This pillar is the oldest and most established, and the ARNI version is the clearest single upgrade in heart failure treatment of the last decade.
What's still uncertain
- Who should start directly on an ARNI rather than switching.
- The best approach when blood pressure limits the dose.
Read more
- NHLBI: Heart failure treatmentGovernment
- American Heart Association: heart failure resourcesNonprofit
- MedlinePlus: Heart failureGovernment
Next: Pillar two
Beta blockers
What happens
The counterintuitive one.
What the research shows
- Beta blockers reduce heart rate and the force of contraction, which sounds exactly wrong for a weak heart, and for years they were considered contraindicated.
- Trials in the 1990s showed the opposite: they substantially reduce death, by removing chronic adrenaline drive that is toxic to heart muscle.
- Only specific agents have proven benefit in heart failure: carvedilol, bisoprolol, and metoprolol succinate. They are not interchangeable with other beta blockers.
- They are started at a low dose when the person is not fluid overloaded, and increased slowly, typically every two weeks.
- Symptoms may worsen slightly in the first weeks before improving, which is why slow titration and an explanation matter.
- They are not stopped abruptly, since that can provoke rapid heart rates and ischaemia.
Why it matters
The beta blocker story is the clearest case in cardiology where the obvious reasoning was wrong and only the trials revealed it.
What's still uncertain
- The optimal target heart rate.
- Whether beta blockers help in atrial fibrillation with heart failure as much as in sinus rhythm.
Read more
- NHLBI: Heart failure treatmentGovernment
- American Heart Association: heart failure resourcesNonprofit
- American College of Cardiology: heart failure guideline resourcesNonprofit
Next: Pillar three
Mineralocorticoid receptor antagonists
What happens
Blocking aldosterone.
What the research shows
- Spironolactone and eplerenone block aldosterone, which otherwise drives sodium retention and fibrosis in the heart.
- They reduce death and hospital admission, and the benefit is separate from their mild diuretic effect.
- The main risk is a rise in potassium, so potassium and kidney function are checked within one to two weeks of starting and regularly afterwards.
- They are used cautiously or avoided when kidney function is significantly impaired or potassium is already high.
- Spironolactone can cause breast tenderness or enlargement in men; eplerenone is an alternative without that effect.
- These are low doses used for the heart, quite different from the higher doses used as a diuretic in liver disease.
Why it matters
This pillar is the most often omitted of the four, usually over potassium concerns that monitoring can manage.
What's still uncertain
- How best to manage potassium while keeping the drug.
- Whether these agents help in HFpEF.
Read more
- NHLBI: Heart failure treatmentGovernment
- American Heart Association: heart failure resourcesNonprofit
- MedlinePlus: Heart failureGovernment
Next: Pillar four
SGLT2 inhibitors
What happens
A diabetes drug that changed heart failure.
What the research shows
- Dapagliflozin and empagliflozin, developed to lower blood sugar, reduce heart failure hospitalisation and cardiovascular death.
- The benefit appears in people with and without diabetes, so these are prescribed as heart failure drugs in their own right.
- They work across the whole range of ejection fraction, including the preserved type, which no previous drug class had managed.
- The mechanism is not fully explained and does not appear to be glucose lowering. Reduced cardiac and kidney stress, improved energy handling and a mild diuretic effect are all proposed.
- They also slow progression of chronic kidney disease, which commonly accompanies heart failure.
- Side effects are mainly genital yeast infections. They are held during serious illness or prolonged fasting because of a small risk of ketoacidosis.
Why it matters
This class is the reason people with HFpEF finally have a treatment with proven outcome benefit, and it arrived from an entirely different field.
What's still uncertain
- How the benefit actually works.
- Whether to start all four pillars simultaneously.
Read more
- NHLBI: Heart failure treatmentGovernment
- American Heart Association: heart failure resourcesNonprofit
- American College of Cardiology: heart failure guideline resourcesNonprofit
Next: Using them together
Order, doses and the gap in practice
What happens
All four beats any one.
What the research shows
- Trials tested each drug added to the others, and estimates of combined treatment suggest several additional years of survival compared with older regimens.
- Current practice favours starting all four quickly at low doses rather than maximising one before adding the next, because the early benefit of each is substantial.
- Doses are increased over weeks toward trial targets, limited by blood pressure, kidney function, potassium and heart rate.
- A low dose of all four is better than a full dose of one, which is a genuinely important point for anyone whose blood pressure limits treatment.
- Registry data consistently show many patients on only one or two of the four, or on doses far below target.
- Other medicines are added in specific situations: hydralazine with nitrate, ivabradine for a persistently fast heart rate, vericiguat, digoxin, and intravenous iron for iron deficiency.
Why it matters
The most common treatment failure in heart failure is not a drug that does not work. It is three of the four never being started.
What's still uncertain
- The optimal sequence and speed of initiation.
- How to close the gap between guidelines and practice.
Read more
- American Heart Association: heart failure resourcesNonprofit
- NHLBI: Heart failure treatmentGovernment
- American College of Cardiology: heart failure guideline resourcesNonprofit
Next: HFpEF
What differs
What happens
Fewer options, but no longer none.
What the research shows
- For decades no treatment improved outcomes in heart failure with preserved ejection fraction, and care was limited to diuretics and treating the associated conditions.
- SGLT2 inhibitors now have proven benefit and are recommended for this group.
- Mineralocorticoid receptor antagonists and ARNIs have shown benefit in parts of the range, particularly at the lower end of preserved ejection fraction.
- Treating what drives it remains central: blood pressure control, weight reduction, atrial fibrillation management, sleep apnea treatment and diabetes care.
- Weight loss, including with GLP-1 medicines in people with obesity-related HFpEF, improves symptoms and exercise capacity in trials.
- Exercise training improves symptoms and quality of life, with good evidence in this group specifically.
Why it matters
HFpEF treatment is now a real list rather than an apology, which is a recent change worth knowing about.
What's still uncertain
- Which additional drugs will prove effective.
- Whether HFpEF subtypes need different treatments.